C-Path's New Paper in Nature Reviews Drug Discovery Highlights How to Maximize the Regulatory Impact of Consortium-Based Projects

Critical Path Institute Belgium Netherlands

and Mastodon.

About Critical Path Institute

Founded in 2005, as a public-private partnership in response to the FDA's Critical Path Initiative, Critical Path Institute® (C-Path) celebrates its 20th anniversary as a vital, independent, nonprofit. C-Path's mission is to lead collaborations that advance better treatments for people worldwide. Globally recognized as a pioneer in accelerating drug development, C-Path has established numerous international consortia, programs and initiatives that currently include more than 1,600 scientists and representatives from government and regulatory agencies, academia, patient organizations, disease foundations and pharmaceutical and biotech companies. With dedicated team members located throughout the world, C-Path's global headquarters is located in Tucson, Arizona and C-Path's Europe subsidiary is headquartered in Amsterdam, Netherlands. For more information, visit c-path.org and follow C-Path on LinkedIn, X, Facebook, Instagram, BlueSky and YouTube.

Media Contacts:

Catherine Brett
External Relations Manager
[e-mail]
[phone]

Roxan Triolo Olivas
C-Path Communications
[e-mail]
[phone]

Logo - https://mma.prnewswire.com/media/2682850/5371567/Crit_Path_20_years_logo_color.jpg

 

View original content:https://www.prnewswire.co.uk/news-releases/c-paths-new-paper-in-nature-reviews-drug-discovery-highlights-how-to-maximize-the-regulatory-impact-of-consortium-based-projects-302482766.html